Search Results

Waters Corporation (NYSE:WAT) and Genovis AB (Nasdaq First North Growth Market) are formally collaborating to develop and market complete routine biopharmaceutical characterization workflows based on the Waters™ BioAccord™ LC-MS System, Andrew+ pipetting robot and Genovis SmartEnzymes™.

Genovis continues to expand their product line of SmartEnzymes for Glycobiology by launching Immobilized SialEXO at the Antibody Engineering and Therapeutics conference in San Diego. Application data developed in collaboration with ProteinSimple, an industry leader within capillary electrophoresis, will be presented in a joint poster at the conference.

Genovis has chosen to apply IFRS 16 in advance, as well as the simplification rule regarding short-term leases.

Genovis expands its portfolio of glycan specific enzymes with the launch of SialEXO 23. A new member of the SialEXO family, SialEXO 23 is an enzyme for study of a specific type of sugar on biopharmaceuticals.

Today Genovis is initiating sales of the FabRICATOR-HPLC column for quality assessment of antibodies in automated analytical systems.

Genovis became certified to ISO 9001:2015 Quality certification means that the management system meets the requirements imposed by International Standard ISO 9001:2015. The certification covers product development, production and sales.

Genovis is continuing to expand in Asia and has signed a distribution agreement with Allianz Bioinnovation for the Indian market.

With the addition of GlycOCATCH, Genovis is expanding its already unique offering of products within the field of O-glycans and streangthens its position as an innovator in this market.

Selecta Biosciences, Inc. today announced a strategic licensing agreement to advance a next-generation IgG protease.

Quality certification means that the management system meets the requirements imposed by International Standard ISO 9001:2015. The certification covers product development, production and sales.